Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

NCT03654768 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

81

Enrollment

NETWORK

Sponsor class

Conditions

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions

DRUG: Bosutinib
DRUG: Dasatinib
OTHER: Laboratory Biomarker Analysis
DRUG: Nilotinib
DRUG: Ruxolitinib
DRUG: Imatinib

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]